By19 August 2015
The “smart drug” modafinil actually does work for some people, improving their performance on long and complex tasks, also enhancing decision-making and planning skills, a new review of studies finds.
Modafinil, also known by its brand name Provigil, is approved by the Food and Drug Administration to treat people with sleep disorders such as narcolepsy. But the majority of the drug’s users — such as students who take it to study for exams — use it off-label, believing it may help them focus. This is despite the lack of strong evidence to date showing that the drug actually works this way.
“This is the first overview of modafinil’s actions in non-sleep-deprived individuals since 2008, and so we were able to include a lot of recent data,” Ruairidh McLennan Battleday, a co-author of the new review and a lecturer at the University of Oxford in England, said in a statement. The recent studies of the drug have used more-complex tests of cognition than those employed previously, and found that modafinil indeed enhances thinking, he said.
In particular, the drug affects the “‘higher-brain functions that rely on contribution from multiple simple cognitive processes,” Battleday said.
The new findings raise ethical concerns about using modafinil, particularly if it gives students an unfair advantage in preparing for or taking tests, the researchers wrote in their review, published online Thursday Aug. 20 in the journal Neuropsychopharmacology.
Past studies showed mixed results for modafinil’s effects on healthy, non-sleep-deprived people. However, for the new paper, the researchers reviewed 24 placebo-controlled studies in healthy people that were published between 1990 and 2014. The studies included more than 700 participants total, and tested a variety of aspects of thinking, including planning and decision-making, flexibility, learning, memory, and creativity. [6 Foods That Are Good for Your Brain]
Modafinil improved only certain features of cognition, the researchers found. In general, the drug appeared to improve what researchers call executive function, the ability to sift through new information and make plans based on it. Modafinil also somewhat enhanced people’s ability to pay attention, learn and remember, the researchers found.
But the drug didn’t consistently help participants on simple tests of attention, the scientists found. It had “little effect on creativity and motor excitability,” they said, and it did not significantly improve people’s working memory, flexibility of thought or ability to divide their attention.
Modafinil has few side effects. The 70 percent of the studies that looked for mood and side effects found only some instances of insomnia, headache, stomachache or nausea, all of which were also reported in placebo groups.
“In the face of vanishingly few side effects in these controlled environments, modafinil can be considered a cognitive enhancer,” said Anna-Katharine Brem, another co-author of the study and a postdoctoral researcher at Oxford.
“However, we would like to stress the point that with any method used to enhance cognition, ethical considerations always have to be taken into account: This is an important avenue for future work to explore,” Brem said.
Follow Laura Geggel on Twitter @LauraGeggel. Follow Live Science @livescience, Facebook & Google+. Original article on Live Science.
Laura is an editor at Live Science. She edits Life’s Little Mysteries and reports on general science, including archaeology and animals. Her work has appeared in The New York Times, Scholastic, Popular Science and Spectrum, a site on autism research. She has won multiple awards from the Society of Professional Journalists and the Washington Newspaper Publishers Association for her reporting at a weekly newspaper near Seattle. Laura holds a bachelor’s degree in English literature and psychology from Washington University in St. Louis and an advanced certificate in science writing from NYU.
Stay up to date on the latest science news by signing up for our Essentials newsletter.
Thank you for signing up to Live Science. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
Live Science is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.
© Future US, Inc. 11 West 42nd Street, 15th Floor, New York, NY 10036.